Washington University

Ceres, Inc.

Monsanto Technology LLC

Vijay K Sharma

Roger I Pennell

Shing Kwok

Michael F Portereiko

Gerard Magpantay

Beth Savidge

Karen Gabbert

Alexander Goldshmidt

Miya Howell

Shunhong Dai

James Burns

Brent Brower-Toland

Han-Suk Kim

Sam Harris

Kenneth Bounds

Ryan Miller

Balasulojini Karunanandaa

Daniel J Ovadya

Sivalinganna Manjunath

David Piwnica-Worms

Elena A Rice

Sasha Preuss

Jothilingam Sivapackiam

Bradley W McDill

Rico A Caldo

Nestor Apuya

Chuan-Yin Wu

Dan Ovadya

Sundaram S M Guruswami

G S M Sundaram

Shimon Gross

Seth Gammon

Brad McDill

Miya D Howell

Bradley W Mcdill

Methods and materials for modulating low light and/or shade tolerance, and red light specific responses in plants are disclosed. For example, nucleic acids encoding low light and/or SD+EODFR-tolerance polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased low light and/or SD+EODFR tolerance. In addition, methods and materials involved in increasing UV-B tolerance in plants and methods and materials involved in modulating biomass levels in plants are provided.

Modulating light response pathways in plants, increasing light-related tolerances in plants, and increasing biomass in plants

The present invention provides recombinant DNA constructs, vectors and molecules comprising a polynucleotide sequence encoding a florigenic FT protein operably linked to a vegetative stage promoter, which may also be a meristem-preferred or meristem-specific promoter. Transgenic plants, plant cells and tissues, and plant parts are further provided comprising a polynucleotide sequence encoding a florigenic FT protein. Transgenic plants comprising a florigenic FT transgene may produce more bolls, siliques, fruits, nuts, or pods per node on the transgenic plant, particularly on the main stem of the plant, relative to a control or wild type plant. Methods are further provided for introducing a florigenic FT transgene into a plant, and planting transgenic FT plants in the field including at higher densities. Transgenic plants of the present invention may thus provide greater yield potential than wild type plants and may be planted at a higher density due to their altered plant architecture.

Compositions and methods for altering flowering and plant architecture to improve yield potential

The present invention provides recombinant DNA constructs, vectors and molecules useful for attenuating and/or refining the expression of a florigenic FT gene or transgene using targeting sequences of small RNA molecules. Transgenic plants, plant cells and tissues, and plant parts comprising the recombinant constructs, vectors, and molecules are also provided. Transgenic plants comprising a florigenic FT transgene may produce more bolls, siliques, fruits, nuts, or pods per node on the transgenic plant via suppression, relative to a control or wild type plant. Methods are further provided for introducing the recombinant DNA constructs, vectors, and molecules into a plant, and planting transgenic plants in the field including at higher densities. Transgenic plants of the present invention may provide greater yield potential than wild type or control plants.

Provided herein are compounds for the imaging and treatment of TDP43-mediated disorders. The compounds disclosed bind TDP43 aggregates and may be used to diagnose and treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Organomedicinals for imaging and treatment of neurodegenerative disorders

Among the various aspects of the present disclosure is the provision of compositions and methods for imaging and treating subjects with amyloidosis or multiple myeloma with or without amyloidosis.

Compositions and methods for AL amyloid detection and uses thereof

Probes which target diffuse and fibrillar forms of amyloid beta (A&#x3b2;) are described. These probes demonstrate high initial brain penetration and facile clearance from non-targeted regions. The agents can be used to image amyloid quantitatively for monitoring efficacy of A&#x3b2;-modifying therapeutics and assist in premortem diagnosis of Alzheimer's disease (AD). Disclosed probes can bind A&#x3b2; aggregates of preformed A&#x3b2;fibrils in vitro and can be used to image fibrillar and diffuse plaques ex vivo in brain sections. Disclosed probes can be used to determine A&#x3b2; burden in early stages of AD. These probes can be used for multimodality imaging of A&#x3b2;. F-AI-187 (1 &#x3bc;M) can detect A&#x3b2; plaques in brain sections of APP/PS1 mice. F-AI-187 (10 &#x3bc;M) can detect A&#x3b2; plaques in the frontal lobe in a brain section of a patient with confirmed AD. Some probes can be used for fluorescence imaging of plaque.

Heterocyclic molecules for biomedical imaging and therapeutic applications

Tracers that can be used for PET or SPECT imaging of the distribution of Pgp are disclosed. The tracers are metalloprobes that can comprise a radioactive metal ion such asGa orGa. Methods of synthesizing the tracers, and methods of imaging heart and other tissues are also disclosed. The tracers can be used to obtain high signal-to-background ratios for imaging tissues in vivo such as heart or tumor tissue. In various embodiments, disclosed tracers can exhibit, a) enhanced first pass extraction into heart tissue compared to presently available probes, b) linearity with true blood flow, c) enhanced detection of myocardial viability compared to presently available probes, d) reduced liver retention compared to presently available probes, and e) more efficient clearance from non-cardiac and adjoining tissues compared to presently available probes.

PET/SPECT agents for applications in biomedical imaging

Methods and materials for modulating biomass levels in plants are disclosed. For example, nucleic acids encoding biomass-modulating polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased biomass levels and plant products produced from plants having increased biomass levels.

Transgenic plants having increased biomass

Methods of imaging distribution of myeloperoxidase activity in a subject are disclosed. These methods include the use of bioluminescent substrates, including luminol and wavelength-shifted analogues of luminol. Bioluminescent myeloperoxidase substrates that emit light at longer wavelengths compared to luminol are shown to be useful for imaging myeloperoxidase activity in vivo. The disclosed methods can be used for imaging sites of inflammation and other pathological conditions associated with abnormal levels of MPO activity in vivo. Methods of synthesis of luminol analogues are also disclosed.

Bioluminescence imaging of myeloperoxidase activity in vivo, methods, compositions and apparatuses therefor

Novel blood-brain barrier permeant amyloid-targeting peptides and peptide conjugates are described. The peptide conjugates include a radioisotope or other label in a stable complex that translocates across brain capillary endothelial cell monolayers. The labeled peptide conjugate binds to amyloid plaques (A&#x3b2;) associated with Alzheimer's disease, and is useful for the targeted delivery of therapeutic and diagnostic molecules into the brain.

Blood brain barrier permeation peptides

Growing community of inventors

Wildwood, MO, United States of America

Vijay K Sharma